Myasthenia Gravis a Manual for the Health Care Provider

Total Page:16

File Type:pdf, Size:1020Kb

Myasthenia Gravis a Manual for the Health Care Provider Myasthenia Gravis A Manual for the Health Care Provider James F. Howard, Jr., M.D., Editor Table of Contents Chapter 1 - Historical Notes Chapter 2 - Physician Issues James F. Howard, Jr. Chapter 3 - Nursing Issues Tina M. Vassar, Madeleine Batenjany, Wilma J. Koopman, Marilyn M. Ricci Chapter 4 - Anesthesia Issues Brian Barrick, and Robert Kyle Chapter 5 - Emergency Care Issues H. Alexander Krob Chapter 6 - Psychosocial Issues: From Diagnosis to Lifetime Management Kimberly M. Johnson Chapter 7 - Physical Therapy Issues Michael Thomas Chapter 8 - Occupational Therapy Issues Timothy Holmes Chapter 9 - Speech Pathology and Swallowing Issues Susan G. Butler Chapter 10 - Dental Care Issues Loren L. Patton Chapter 11 - Guidelines for the Pharmacist James F. Howard Chapter 12 - Myasthenia Gravis Foundation of America Chapter 13 - Appendices 2 Myasthenia Gravis Foundation of America Readers are advised to check the most current information 355 Lexington Ave, 15th Floor available. It is the responsibility of the health care provider, New York, NY 10017 relying on their own knowledge and experience to make diag- noses, determine appropriate treatment, doses and schedules Myasthenia Gravis: A Manual for the Health Care Provider and overall best treatment plan for the pateint. ISBN: 0981888305 To the fullest extent of the law, neither the Publisher, Editor Copyright © 2009 by or Authors assume any liablility for any injury and or damages Myasthenia Gravis Foundation of America to persons or property arising out or related to any use of the All rights reserved. No part of this publication may be repro- material contained in this book. duced or transmitted in any form or by any means, electronic The Publisher or mechanical, including photocopying, recording, or any in- formation storage and retrieval system, without permission in Library of Congress Cataloging-in-Publication Data writing from the publisher other than photocopies of single chapters for personal use as allowed by national copyright Library of Congress Control Number: 2008932503 laws. Myasthenia Gravis: A Manual for the Health Care Provider, Permissions may be sought directly from the Myasthenia edited by James F. Howard, Jr. Gravis Foundation of America, 355 Lexington Ave, 15th Floor New York, NY 10017, USA: phone: (212) 297-2156, 1st ed. email: [email protected]. Cover photo, page 28 by: Mario Beaurgard / Stock Connection Includes biographical references and index / Jupiter Images ISBN: 0981888305 Notice 1. Neurology 2. Nervous system - Diseases 3. Myasthenia Gra- Knowledge and best practice in the field of Myasthenia Gravis vis I. Howard, J. F. (James Francis) Printed in USA is constantly changing as new research and experience broad- ens the knowledge base. Changes in practice, treatment and therapy may be necessary or appropriate. Preface 3 Chronic Condition Program – Specialty Groups Acknowledgments Blue Cross Blue Shield of Michigan This book is the product of the efforts of many people. First Susan G. Butler, Ph.D., CCC-SLP and foremost we thank the MG community who has taught us Associate Professor about Myasthenia Gravis. Their stories and insights into the Department of Otolaryngology problems faced by myasthenics helped shape our understand- Wake Forest University Baptist Medical Center ing of this disorder. Winston-Salem, NC MGFA wishes to express its gratitude and thanks to the Wis- Timothy Holmes, OTR/L, COMS consin Chapter of the Myasthenia Gravis Foundation of Amer- Department of Physical and Occupational Therapy ica, Janice Edelman-Lee at Chodoy Design, and Ron McFar- UNC Healthcare lane at MedPro Rx, and all of those whose generosity and sup- The University of North Carolina Hospitals port have allowed this project come to fruition. Your commit- Chapel Hill, NC ment was the driving force to develop the best possible re- source for community health care providers. James F. Howard, Jr., M.D. Distinguished Professor of Neuromuscular Disease List of Contributors Professor of Neurology & Medicine Chief, Neuromuscular Disorders Section Brian P. Barrick, D.D.S., M.D. Department of Neurology Assistant Professor The University of North Carolina at Chapel Hill Department of Anesthesiology School of Medicine The University of North Carolina at Chapel Hill Chapel Hill, NC School of Medicine Kimberly M. Johnson, M.S.W., L.C.S.W., C.C.M. Chapel Hill, NC Department of Clinical Care Management Madeleine Batenjany, R.N., M.S.N., ANP-C UNC Healthcare Case Manager The University of North Carolina Hospitals Premium Blue Health Connection Chapel Hill, NC Preface 4 Wilma J. Koopman, R.N., B.Sc.N., M.Sc.N., T.C.N.P. Marilyn M. Ricci, R.N., M.S., CNS, CNRN C.N.N.(C) Adjunct Faculty, Neuroscience Clinical Nurse Specialist Advanced Practice Nurse Learning Institute London Health Sciences Centre St. Joseph’s Hospital & Medical Center Assistant Professor and Lecturer School of Nursing Faculty of Phoenix, Arizona Health Sciences Michael Thomas, L.P.T. University of Western Ontario Department of Physical and Occupational Therapy London, CANADA WakeMed Health & Hospitals H. Alexander Krob, M.D. Raleigh, NC Instructor and Fellow in Neuromuscular Disease Tina M. Vassar, R.N. Department of Neurology Chapel Hill, NC The University of North Carolina at Chapel Hill School of Medicine Chapel Hill, NC Preface Robert W. Kyle, D.O. The mission statement of the Myasthenia Gravis Foundation Assistant Professor of America (MGFA) is to facilitate the timely diagnosis and op- Department of Anesthesiology timal care of individuals affected by myasthenia gravis (MG) The University of North Carolina at Chapel Hill and closely related disorders and to improve their lives School of Medicine through programs of patient services, public information, Chapel Hill, NC medical research, professional education, advocacy and pa- tient care. Since, at present, there is no cure, there must be a Lauren L. Patton, D.D.S. consistent, interdisciplinary effort by all allied health profes- Professor sionals to appropriately evaluate and treat patients with MG. Director, GPR Residency Program Department of Dental Ecology This handbook is written as an aide to all healthcare person- School of Dentistry nel who are involved in the care and management of patients The University of North Carolina at Chapel Hill with myasthenia gravis. Sections are included to assist the phy- Chapel Hill, NC sician community in their evaluation, diagnosis and manage- Preface 5 ment of MG. Every effort has been made to outline the varying and will be able to supply the physician with more detailed in- opinion of the experts and it is recognized that more than one formation about current treatment efficacy. approach may be appropriate. The over riding principle that The pharmacist plays an important role in the safety and edu- patients with MG are not in a vacuum and must be evaluated cation of the myasthenic patient. Today’s healthcare system and treated based on their entire health care picture is neces- often depends upon the specialist who has little knowledge of sary. The perspective of an anesthesiologist and dentist are other disciplines. The ever growing list of drug-drug interac- also included because their interaction with the myasthenic tions that may be harmful to the patient places the pharmacist patient is unique and special considerations are necessary. in a central position to be the watchdog and keep the patient Nursing plays a critical role in the day-to-day management of out of harms way. the hospitalized and community patient. A team approach to This coordinated, interdisciplinary approach will promote in- the patient will inevitably result in the optimal care of the my- creased quality of life for those affected by myasthenia gravis. asthenic patient. The following guidelines are a culmination of over 35 years of The patient with a chronic illness faces numerous obstacles in clinical practice in university-based teaching hospitals. It is their every day life. The clinical social worker is invaluable to the authors’ hope that these guidelines will challenge all allied the patient (and the healthcare team) in navigating the bu- health clinicians who work with patients diagnosed with myas- reaucracy and hurdles as it pertains to insurance, financial as- thenia gravis to critically evaluate their current practice with sistance and psychosocial well being. respect to these patients. We submit that incorporation of The allied health evaluations should be objective and quantita- these recommendations into the evaluation and treatment rep- tive for each individual patient and should assist the physician ertoire of allied health professionals will enhance the quality in diagnosis, classification and effectiveness of medical treat- of care provided to people who have myasthenia gravis. ment. These evaluations should enable the allied health profes- sionals to determine a functional baseline and an appropriate exercise prescription. The patient will then be able to utilize a program of moderate-intensity exercise to improve his/her level of fitness, which will diminish the effect of exacerbations. Through the use of self-monitored exercise, each patient will have an improved sense of his/her own functional limitations Preface 6 1 Historical Notes James F. Howard, Jr. The unraveling of the molecular mechanisms of Myasthenia Gravis (MG) over the last three centuries has resulted in what we know today about the pathogenesis of MG and the rationale for its present and future treatments. The first descriptions of MG cases occurred more than 300 years ago, yet it was not until a series of discoveries in the early and mid 1970s that an understanding of and the general consensus that MG symptoms are due to an autoimmune response to the acetylcholine receptor (AChR) complex on the post-junctional membrane of the neuromuscular junction The first two cases of a disease that was likely to be MG were and died in 1664. Marsteller concluded that Opechankanough described several centuries ago; one on the American conti- developed MG late in life when he was between 70 and 90 nent and one in Europe.
Recommended publications
  • Neuromyelitis Optica in Patients with Myasthenia Gravis Who Underwent Thymectomy
    ORIGINAL CONTRIBUTION Neuromyelitis Optica in Patients With Myasthenia Gravis Who Underwent Thymectomy Ilya Kister, MD; Sandeep Gulati, MD; Cavit Boz, MD; Roberto Bergamaschi, MD; Guiseppe Piccolo, MD; Joel Oger, MD; Michael L. Swerdlow, MD Background: Myasthenia gravis (MG) and neuromy- Patients: Four patients with MG who underwent elitis optica (NMO, also known as Devic disease) are rare thymectomy. autoimmune disorders, with upper-limit prevalence es- timates in the general population of 15 per 100 000 and Interventions: None. 5 per 100 000, respectively. To our knowledge, an asso- ciation between these diseases has not been previously Results: The prevalence of MG within the published co- reported. hort of patients with NMO is more than 150 times higher than that in the general population. Objectives: To describe 4 patients with MG who de- Conclusion: Dysregulation of B-cell autoimmunity in my- veloped NMO after thymectomy and to analyze possible asthenia, possibly exacerbated by loss of control over au- causes of apparent increased prevalence of NMO among toreactive cells as a result of thymectomy, may predis- patients with MG. pose patients to the development of NMO. Design: Case series. Arch Neurol. 2006;63:851-856 EUROMYELITIS OPTICA REPORT OF CASES (NMO) is characterized by 1 or more attacks of CASE 1 optic neuritis (ON) and myelitis. It can be dif- An African American woman with mild Nferentiated from multiple sclerosis (MS) asthma, distant history of smoking and with the aid of magnetic resonance imag- cocaine snorting, and family history of ing (MRI),1-3 cerebrospinal fluid anal- MS in her mother developed symptoms ysis4-8 and NMO-IgG antibody.9 The of ocular myasthenia at age 38 years.
    [Show full text]
  • A Schematic Approach to Hypotonia in Infancy
    Leyenaar.qxd 8/26/2005 4:03 PM Page 397 NEUROLOGY SUBSPECIALTY ARTICLE A schematic approach to hypotonia in infancy JoAnna Leyenaar MD MPH, Peter Camfield MD FRCPC, Carol Camfield MD FRCPC J Leyenaar, P Camfield, C Camfield. A schematic approach Une démarche schématique envers l’hypotonie to hypotonia in infancy. Paediatr Child Health 2005; pendant la première enfance 10(7):397-400. L’hypotonie peut être le signe révélateur de nombreuses maladies Hypotonia may be the presenting sign for many systemic diseases and systémiques ou du système nerveux. Le présent article traite d’une diseases of the nervous system. The present paper discusses a rational, démarche diagnostique rationnelle, simple et précise envers l’hypotonie simple and accurate diagnostic approach to hypotonia in infancy, pendant la première enfance, illustrée par le cas d’une fillette de cinq mois illustrated by the case of a five-month-old infant girl recently referred récemment aiguillée vers le IWK Health Centre de Halifax, en Nouvelle- to the IWK Health Centre in Halifax, Nova Scotia. Key points in the Écosse. Les principaux points de l’anamnèse et de l’examen physique sont history and physical examination are outlined to allow a tailored exposés afin de permettre une exploration personnalisée de la patiente et investigation both for the patient and for other hypotonic infants. A des autres nourrissons hypotoniques. Un exposé sur une importante discussion of an important neuromuscular disease, diagnosed in the maladie neuromusculaire, diagnostiquée chez la patiente, conclut l’article. present patient, concludes the paper. Key Words: Hypotonia; Infant; Spinal muscular atrophy nfants with hypotonia pose challenges for clinicians respiratory syncytial virus-positive bronchiolitis.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Severe Asthma Associated with Myasthenia Gravis and Upper Airway Obstruction a Souza-Machado,1,2 E Ponte,2 ÁA Cruz2
    Severe Asthma and Myasthenia Gravis CASE REPORT Severe Asthma Associated With Myasthenia Gravis and Upper Airway Obstruction A Souza-Machado,1,2 E Ponte,2 ÁA Cruz2 1Pharmacology Department, Bahia School of Medicine and Public Health, Universidade Federal da Bahia, Salvador–Bahia, Brazil 2Asthma and Allergic Rhinitis Control Program (ProAR), Bahia Faculty of Medicine, Universidade Federal da Bahia, Salvador–Bahia, Brazil ■ Abstract An unusual association of asthma and myasthenia gravis (MG) complicated by tracheal stenosis is reported. The patient was a 35-year-old black woman with a history of severe asthma and rhinitis over 30 years. A respiratory tract infection triggered a life-threatening asthma attack whose treatment required orotracheal intubation and mechanical ventilatory support. A few weeks later, tracheal stenosis was diagnosed. Clinical manifestations of MG presented 3 years after her near-fatal asthma attack. Spirometry showed severe obstruction with no response after inhalation of 400 µg of albuterol. Baseline lung function parameters were forced vital capacity, 3.29 L (105% predicted); forced expiratory volume in 1 second (FEV1), 1.10 L (41% predicted); maximal midexpiratory fl ow rate, 0.81 L/min (26% predicted). FEV1 after administration of albuterol was 0.87 L (32% predicted). The patient’s fl ow–volume loops showed fl attened inspiratory and expiratory limbs, consistent with fi xed extrathoracic airway obstruction. Chest computed tomography scans showed severe concentric reduction of the lumen of the upper thoracic trachea. Key words: Asthma. Tracheal stenosis. Myasthenia gravis. Exacerbation. ■ Resumen En este caso informamos de una asociación infrecuente entre el asma y la miastenia grave (MG) complicada por estenosis traqueal.
    [Show full text]
  • Data Driven Investigation of Bispectral Index Algorithm
    www.nature.com/scientificreports OPEN Data Driven Investigation of Bispectral Index Algorithm Hyung-Chul Lee, Ho-Geol Ryu, Yoonsang Park , Soo Bin Yoon, Seong Mi Yang, Hye-Won Oh & Chul-Woo Jung Received: 7 January 2019 Bispectral index (BIS), a useful marker of anaesthetic depth, is calculated by a statistical multivariate Accepted: 9 September 2019 model using nonlinear functions of electroencephalography-based subparameters. However, only Published: xx xx xxxx a portion of the proprietary algorithm has been identifed. We investigated the BIS algorithm using clinical big data and machine learning techniques. Retrospective data from 5,427 patients who underwent BIS monitoring during general anaesthesia were used, of which 80% and 20% were used as training datasets and test datasets, respectively. A histogram of data points was plotted to defne fve BIS ranges representing the depth of anaesthesia. Decision tree analysis was performed to determine the electroencephalography subparameters and their thresholds for classifying fve BIS ranges. Random sample consensus regression analyses were performed using the subparameters to derive multiple linear regression models of BIS calculation in fve BIS ranges. The performance of the decision tree and regression models was externally validated with positive predictive value and median absolute error, respectively. A four-level depth decision tree was built with four subparameters such as burst suppression ratio, power of electromyogram, 95% spectral edge frequency, and relative beta ratio. Positive predictive values were 100%, 80%, 80%, 85% and 89% in the order of increasing BIS in the fve BIS ranges. The average of median absolute errors of regression models was 4.1 as BIS value.
    [Show full text]
  • Invasive Aspergillosis Poster IDSA FINAL Pdf.Pdf
    Invasive Aspergillosis Associated with Severe Influenza Infections Nancy Crum-Cianflone MD MPH Scripps Mercy Hospital, San Diego, CA USA Abstract Background (cont.) Results Results (cont.) Background: Bacterial superinfections are well-described complications of influenza • Typically, invasive aspergillosis occurs among severely immunosuppressed hosts Case-Control Study • Systematic Review of the Literature infection, however few data exist on invasive fungal infections in this setting. The Hematologic malignancies, neutropenia, and transplant recipients 48 medical ICU patients underwent influenza testing; 8 were diagnosed with influenza N=52 and present cases (n=5) = 57 total cases • All influenza-positive patients had ventilator-dependent respiratory failure A summary of the cases is shown in Table 2 pathogenesis of invasive aspergillosis may be related to respiratory epithelium • Isolation of Aspergillus sp. in the immunocompetent host without these conditions may be initially considered as a colonizer or non-pathogen Of the 8 patients with severe influenza infection, six (75%) had Aspergillus sp. isolated Increasing number of cases over time: disruption and viral-induced lymphopenia. • 4 A. fumigatus, 1 A. fumigatus and A. versicolor, and 1 A. niger isolated • First cases described in 1979, followed by three cases in the 1980s, two cases in the 1990s, two cases in • However, recent cases have suggested that Aspergillus may rapidly lead to invasive • Since A. niger was of unknown pathogenicity this case was excluded the 2000’s, and 48 cases from 2010 to the 1st quarter of 2016 demonstrating an increasing trend of aspergillosis superinfection (p<0.001) Methods: A retrospective study was conducted among severe influenza cases requiring disease in the setting of severe influenza infection [2,3] Of the 40 patients negative for influenza admitted to the same ICU, none had Aspergillus ICU admission at a large academic hospital (2015-2016).
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Targeting the Rare Co-Occurrence of Myasthenia Gravis and Graves’ Disease with Radioactive Iodine Therapy
    ID: 21-0046 -21-0046 A E S Arcellana and others Myasthenia gravis, Graves’ ID: 21-0046; July 2021 disease association DOI: 10.1530/EDM-21-0046 Dual attack: targeting the rare co-occurrence of myasthenia gravis and Graves’ disease with radioactive iodine therapy Correspondence Anna Elvira S Arcellana 1, Karen Joy B Adiao2 and Myrna Buenaluz-Sedurante1 should be addressed to A E S Arcellana 1Division of Endocrinology, Diabetes and Metabolism, Department of Medicine and 2Department of Neurosciences, Email University of the Philippines-Manila, Philippine General Hospital, Manila, Philippines [email protected] Summary Occasionally, autoimmune disorders can come in twos. This double trouble creates unique challenges. Myasthenia gravis co-existing with autoimmune thyroid disease occurs in only about 0.14–0.2% of cases. The patient is a 27-year- old man with a 2-month history of bilateral ptosis, diplopia, with episodes of easy fatigability, palpitations, and heat intolerance. On physical exam, the patient had an enlarged thyroid gland. Myasthenia gravis was established based on the presence of ptosis with weakness of the intraocular muscles, abnormal fatigability, and a repetitive nerve stimulation studyindicatedneuromuscularjunctiondisease.Episodesoffluctuatingrightshoulderweaknesswerealsonoted.He wasalsofoundtohaveelevatedFT3,FT4,andasuppressedTSH.Thyroidultrasoundrevealedthyromegalywithdiffused parenchymal disease. Thyroid scintigraphy showed increased uptake function at 72.4% uptake at 24 h. TRAb was positive at4.1U/L.Patientwasstartedonpyridostigminewhichledtoasignificantreductioninthefrequencyofocularmuscle weakness.Methimazolewasalsoinitiated.Radioactiveiodineat14.9mciwasinstitutedforthedefinitivemanagementof hyperthyroidism. After RAI, there was abatement of the hyperthyroid symptoms, as well as improvement in the status of the myasthenia gravis, with ptosis, diplopia, and right arm weakness hardly occurring thereafter despite the reduction of the pyridostigmine dose based on a symptom diary and medication intake record.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Myasthenia Gravis
    FACT SHEET FOR PATIENTS AND FAMILIES Myasthenia Gravis What is myasthenia gravis? How is it diagnosed? Myasthenia [mahy-uh s-THEE-nee-uh] gravis is a disease Your doctor will ask you about your symptoms, where the body’s immune system attacks the perform a physical examination, and review all of connection between the nerve and muscle, causing your blood work and other tests. More blood work weakness. might be ordered to look for signs that the immune system might be attacking the muscles. A doctor may What causes it? What are the risk also perform a nerve conduction study known as factors? electromyography [ih-lek-troh-mahy-OG-ruh-fee} or EMG. Myasthenia gravis is an autoimmune [aw-toh-i-MYOON] An EMG records the electrical activity of muscles. disease. It occurs when the parts of the immune system that normally attack bacteria and viruses What are the complications? (antibodies) accidentally attack the connection If symptoms become severe, you may not be able between the nerve and muscle, also known as the to breathe normally or swallow saliva or food. This neuromuscular [noor-oh-MUHS-kyuh-ler] junction. results in aspiration [as-puh-REY-shuh n], where food or saliva goes into your airway. Serious complications The antibodies block a chemical called acetylcholine like these can result in injury or even death if left [uh-seet-l-KOH-leen], which is released by the nerve untreated. ending to activate the muscle, creating movement. Blocking this chemical causes weakness. How is it treated? Risk factors for myasthenia gravis include having a Mild symptoms are treated with a medicine called personal or family history of autoimmune diseases.
    [Show full text]
  • Multiple Sclerosis Associated with Defects in Neuromuscular Transmission
    Journal ofNeurology, Neurosurgery, and Psychiatry, 1972, 35, 385-394 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.35.3.385 on 1 June 1972. Downloaded from Multiple sclerosis associated with defects in neuromuscular transmission BERNARD M. PATTEN, AVERY HART, AND ROBERT LOVELACE' From The Neurological Clinical Research Center, Department ofNeurology, College ofPhysicians andSurgeons, Columbia University, New York City, U.S.A. SUMMARY Three patients with multiple sclerosis characterized by exacerbations and remissions of nervous system signs and symptoms disseminated in time and space also had the kind of easy fatigu- ability seen in myasthenia gravis. In each case abnormal decrements to repetitive stimulation were electromyographically demonstrated and treatment with ephedrine or anticholinesterase drugs increased the patient's functional capacity while improving the electromyographic abnormality. The suggestion is that these patients represent an overlap syndrome, analogous to the overlap syndrome existing between systemic lupus erythematosus and rheumatoid arthritis where clinical and laboratory features of two diseases coexist in the same patient at the same time. Presumably some patients with multiple sclerosis have deficient production of acetylcholine, just like patients with myasthenia, and treatment with agents useful in myasthenia is able partially to correct the the The cases illustrate how in neurology greater attention to the symptoms caused by deficiency. Protected by copyright. more immediate cause of clinical
    [Show full text]